Natrelle® Awarded Supplier Agreement from Vizient
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has secured a supplier agreement with Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement provides Vizient's network, which represents over 50% of U.S. healthcare organizations, enhanced access to Natrelle®'s comprehensive breast implant line featuring more than 300 implant options.
The partnership offers Vizient clients competitive pricing, simplified procurement, improved operational efficiency, and direct support from Natrelle®'s sales and technical teams. Natrelle®, currently the #1 selected breast implant by plastic surgeons, brings a 50-year legacy of excellence in breast reconstruction and augmentation solutions.
Allergan Aesthetics, una società di AbbVie (NYSE: ABBV), ha stipulato un accordo di fornitura con Vizient, Inc., la più grande azienda statunitense guidata dal network per il miglioramento delle prestazioni sanitarie. L’accordo offre alla rete di Vizient, che rappresenta oltre il 50% delle organizzazioni sanitarie USA, un accesso potenziato alla completa linea di impianti mammari Natrelle® con oltre 300 opzioni di impianto.
La partnership propone ai clienti Vizient tariffe competitive, approvvigionamento semplificato, maggiore efficienza operativa e supporto diretto dai team di vendita e tecnico di Natrelle®. Natrelle®, attualmente la prima scelta tra gli impianti mammari dei chirurghi plastici, vanta una storia di 50 anni di eccellenza nelle soluzioni per la ricostruzione e l’aumento del seno.
Allergan Aesthetics, una empresa de AbbVie (NYSE: ABBV), ha asegurado un acuerdo de suministro con Vizient, Inc., la mayor compañía de mejora del rendimiento de atención sanitaria impulsada por proveedores en Estados Unidos. El acuerdo otorga a la red de Vizient, que representa a más del 50% de las organizaciones de atención médica de EE. UU., un acceso mejorado a la línea completa de implantes mamarios de Natrelle® con más de 300 opciones de implantes.
La asociación ofrece a los clientes de Vizient precios competitivos, adquisición simplificada, mayor eficiencia operativa y apoyo directo por parte de los equipos de ventas y técnicos de Natrelle®. Natrelle®, actualmente el implante mamario elegido número 1 por cirujanos plásticos, cuenta con 50 años de trayectoria de excelencia en soluciones de reconstrucción y aumento de senos.
Allergan Aesthetics, 애버비(AbbVie) 소속(주식코드: NYSE: ABBV)이며, 미국 내 공급자 주도형 의료 성과 개선 분야의 최대 공급자 기업인 Vizient, Inc.와 공급 계약을 체결했습니다. 이 계약은 Vizient의 네트워크(미국 내 의료기관의 50% 이상을 차지하는)에 Natrelle®의 포괄적 유방 임플란트 라인에 대한 더 나은 접근성을 제공합니다. 임플란트 옵션은 300건이 넘습니다.
파트너십은 Vizient 고객에게 경쟁력 있는 가격, 조달 간소화, 운영 효율성 향상 및 Natrelle®의 영업 및 기술 팀으로부터 직접 지원을 제공합니다. Natrelle®은 현재 성형외과 의사들이 가장 많이 선택하는 유방 임플란트로, 유방 재건 및 확대 솔루션에서 50년의 탁월한 역사를 갖고 있습니다.
Allergan Aesthetics, une société d’AbbVie (NYSE: ABBV), a conclu un accord fournisseur avec Vizient, Inc., la plus grande entreprise axée sur l’amélioration des performances des soins de santé guidée par les fournisseurs aux États-Unis. L’accord permet au réseau Vizient, qui représente plus de 50% des organisations de santé américaines, d’avoir un accès renforcé à la ligne complète d’implants mammaires Natrelle® offrant plus de 300 options d’implant.
Le partenariat offre aux clients de Vizient des prix compétitifs, un approvisionnement simplifié, une meilleure efficacité opérationnelle et un soutien direct des équipes de vente et techniques de Natrelle®. Natrelle®, actuellement le implant mammaire le plus utilisé par les chirurgiens plasticiens, bénéficie d’un héritage de 50 ans d’excellence dans les solutions de reconstruction et d’augmentation mammaire.
Allergan Aesthetics, eine Tochtergesellschaft von AbbVie (NYSE: ABBV), hat eine Lieferantenvereinbarung mit Vizient, Inc. getroffen, dem größten anbietergetriebenen Unternehmen zur Leistungsverbesserung im Gesundheitswesen in den USA. Die Vereinbarung ermöglicht dem Vizient-Netzwerk, das mehr als 50 % der Gesundheitsorganisationen in den USA repräsentiert, einen verbesserten Zugang zu der kompletten Natrelle®-Brustimplantatlinie mit über 300 Implantatoptionen.
Die Partnerschaft bietet Vizient-Kunden wettbewerbsfähige Preise, vereinfachte Beschaffung, verbesserte operative Effizienz und direkte Unterstützung durch die Vertriebs- und Technikteams von Natrelle®. Natrelle®, derzeit das am häufigsten von plastischen Chirurgen gewählte Brustimplantat, blickt auf eine 50-jährige Erfolgsgeschichte in Lösungen zur Brustrekonstruktion und -augmentation zurück.
Allergan Aesthetics، شركة تابعة لـ AbbVie (NYSE: ABBV)، عقدت اتفاقية مورد مع Vizient, Inc.، أكبر شركة تحسين أداء الرعاية الصحية مدفوعة من قبل مزودي الخدمة في الولايات المتحدة. توفر الاتفاقية لشبكة Vizient، التي تمثل أكثر من 50% من مؤسسات الرعاية الصحية الأمريكية، وصولاً محسنًا إلى خط Natrelle® الكامل لزراعة الثدي مع أكثر من 300 خيار لزراعة الثدي.
تقدم الشراكة لعملاء Vizient أسعار تنافسية، وتوريدًا مبسطًا، وكفاءة تشغيلية محسنّة، ودعمًا مباشرًا من فرق المبيعات والفنية لدى Natrelle®. Natrelle®، التي تعد حاليًا الزرعة رقم 1 المختارة لزرعات الثدي من قبل جراحي التجميل، تحمل تاريخًا من 50 عامًا من التميّز في حلول إعادة البناء وتكبير الثدي.
Allergan Aesthetics，是 AbbVie 的子公司（NYSE: ABBV），已与美国最大的以供应商为驱动的医疗绩效改进公司 Vizient, Inc. 签订供应商协议。该协议为 Vizient 的网络提供了更广的进入途径，该网络代表了美国超过 50% 的医疗保健机构，获得 Natrelle® 全线乳房植入物，总计超过 300 种植入选项。
该伙伴关系为 Vizient 客户提供有竞争力的定价、简化的采购、提升的运营效率，以及来自 Natrelle® 销售与技术团队的直接支持。Natrelle® 目前是 整形外科医生最常选用的乳房植入物，在乳房重建与增大解决方案方面拥有50年的卓越传承。
- Partnership with Vizient provides access to over 50% of U.S. healthcare organizations
- Natrelle® is the #1 selected breast implant brand by plastic surgeons
- Offers the broadest selection with over 300 implant options
- Agreement includes competitive pricing and simplified procurement process
- Breast implants are not lifetime devices and require ongoing maintenance
- Higher risk of complications over time including potential need for additional surgeries
- Associated with risk of BIA-ALCL cancer, particularly in textured implants
- Potential systemic symptoms reported including joint pain, fatigue, and autoimmune issues
Insights
AbbVie's Natrelle secures Vizient supplier agreement, potentially boosting market reach to over half of U.S. healthcare organizations.
This supplier agreement between Natrelle and Vizient represents a significant market expansion opportunity for AbbVie's aesthetics portfolio. Vizient's network encompasses more than half of U.S. healthcare organizations, including academic medical centers, community hospitals, and integrated delivery networks, creating substantial distribution potential for Natrelle's 300+ breast implant options.
The strategic value of this partnership extends beyond mere product placement. By securing competitive pricing and simplified procurement processes for Vizient clients, AbbVie positions Natrelle to potentially capture greater market share in the breast reconstruction segment. The agreement provides direct access to institutional buyers who influence purchasing decisions across major healthcare systems.
This partnership aligns with AbbVie's diversification strategy following its Allergan acquisition. While breast implants represent a relatively small revenue stream compared to AbbVie's pharmaceutical portfolio, this agreement strengthens the company's presence in the medical aesthetics market. The deal's timing is strategic, occurring as healthcare systems increasingly centralize purchasing through group purchasing organizations like Vizient to control costs.
For context, Natrelle's position as the "number one selected breast implant by plastic surgeons" gives it strong brand recognition in a specialized market where surgeon preference heavily influences product selection. By expanding institutional access through Vizient, AbbVie creates a dual-channel approach, maintaining its direct relationships with surgeons while enhancing its institutional footprint.
This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the market.
Through this contract, Vizient clients will gain enhanced access to Natrelle®'s unmatched offerings, including more than 300 implant options within the most comprehensive breast implant line. Providers will also benefit from competitive pricing, a simplified procurement process, greater operational efficiency, and direct support from the brand's experienced sales and technical teams.
"This agreement with Vizient underscores our commitment to supporting women through their breast reconstruction journeys while equipping providers with the tools they need to deliver exceptional care," said Glen Curran, Senior Vice President,
Built on a 50-year legacy of excellence and innovation, Natrelle® is the number one selected breast implant by plastic surgeons1*. For more information about Natrelle®, please visit www.natrelle.com.
*Based on surgeon survey data, August 2024 (N=478).
Natrelle ® Breast Implants IMPORTANT SAFETY INFORMATION AND APPROVED USES
Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery.
Breast implants have been associated with the development of a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined. Some patients have died from BIA-ALCL.
Patients receiving breast implants have reported a variety of systemic symptoms, such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.
Who can get breast implants?
Natrelle
® Breast Implants are approved for the following:
- Breast augmentation for women at least 22 years old for silicone-filled implants and for women at least 18 years old for saline-filled implants. Breast augmentation includes primary breast augmentation to increase the breast size and revision surgery to correct or improve the result of a primary breast augmentation
- Breast reconstruction. This includes primary breast reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. This also includes revision surgery to correct or improve the result of a primary breast reconstruction
Who should NOT get breast implants?
Breast implant surgery should NOT be performed in:
- Women with active infection anywhere in their body
- Women with existing cancer or precancer of their breast who have not received adequate treatment for those conditions
- Women who are currently pregnant or nursing
What should I tell my doctor?
Tell your doctor if you have any of the following conditions, as the risks of breast implant surgery may be higher:
- Autoimmune diseases (eg, lupus and scleroderma)
- A weakened immune system (eg, taking medications to decrease the body's immune response)
- Planned chemotherapy or radiation therapy following breast implant placement
- Conditions or medications that interfere with wound healing and blood clotting
- Reduced blood supply to breast tissue
- Clinical diagnosis of depression or other mental health disorders, including body dysmorphic disorder and eating disorders
- Those with a diagnosis of depression or other mental health disorders should wait for resolution or stabilization of these conditions prior to undergoing breast implantation surgery
What else should I consider?
- There is a Boxed Warning for breast implants. Please see bold text at beginning
- Many changes to your breasts following implantation are irreversible. If you later choose to have your implants removed and not replaced, you may experience dimpling, puckering, wrinkling, or other cosmetic changes, which may be permanent
- Breast implantation is likely not a one-time surgery. The longer implants are in place, the greater the potential risk for complications. You will likely need additional surgeries on your breasts due to complications or unacceptable cosmetic results. Thus, you should also consider the complication rates for later (revision) surgery since you may experience these risks in the future
- Cancer treatments and surgery will affect the outcome and timing of breast reconstruction
- Breast implants may affect your ability to breastfeed, either by reducing or eliminating milk production
- Rupture of a silicone-filled breast implant is most often silent. Even if you have no symptoms, you should have your first ultrasound or MRI at 5 to 6 years after your initial implant surgery and then every 2 to 3 years thereafter regardless of whether your implants are for augmentation or reconstruction. If you have symptoms of or uncertain ultrasound results for breast implant rupture, an MRI is recommended. Additional imaging may be required depending on your medical history and status. The health consequences of a ruptured silicone gel-filled breast implant have not been fully established
- Routine screening mammography for breast cancer will be more difficult, and implants may rupture during the procedure. Perform self-examination every month for cancer screening and ask your surgeon to help you distinguish the implant from your breast tissue. Lumps, persistent pain, swelling, hardening, or changes in implant shape should be reported to your surgeon and possibly evaluated with imaging
What are key complications with breast implants?
Key complications include reoperation, implant removal with or without replacement, implant rupture with silicone-filled implants, implant deflation with saline-filled implants, and capsular contracture (severe scar tissue around the implant). Other complications include breast pain, swelling, asymmetry, wrinkling/rippling, implant malposition nipple complications, hypertrophic scarring, and implant palpability/visibility.
Talk to your doctor about other complications.
For more information, see the patient brochures at www.allergan.com/products.
To report a problem with Natrelle® Breast Implants, please call Allergan
®
at 1-800-624-4261.
The sale and distribution of Natrelle® Breast Implants is restricted to licensed physicians who provide information to patients about the risks and benefits of breast implant surgery.
About Natrelle®
Natrelle® offers a wide range of breast implant options designed with safety, science, and aesthetics in mind. Backed by over 600 published studies and more than 50 years of research and experience, Natrelle® implants provide patients and surgeons with choices to support personalized outcomes.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skincare, and more. With cutting-edge science and a deep understanding of patients, we are committed to empowering confidence.
References:
- Data on file, Allergan Aesthetics, Monthly Tracker, August 2024.
© 2025 AbbVie. All rights reserved. All trademarks are the property of their respective owners.
Contacts:
Allergan Aesthetics Media:
Ember Garrett
+1 (949) 413-6091
Garrett_ember@allergan.com
AbbVie Investors:
Liz Shea
+1 (847) 935-2211
Liz.Shea@abbvie.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/natrelle-awarded-supplier-agreement-from-vizient-302568579.html
SOURCE AbbVie
FAQ
What is the new agreement between Natrelle® and Vizient for ABBV stock?
How many breast implant options does Natrelle® offer under this agreement?
What are the main safety concerns with Natrelle® breast implants?
Who is eligible for Natrelle® breast implants?
What makes Natrelle® the leading breast implant choice for surgeons?
